In Daiichi case, court upholds jury's $177.8M infringement ruling against Novartis - Fierce Pharma

In Daiichi case, court upholds jury's $177.8M infringement ruling against Novartis  Fierce Pharma

Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection - BioSpace

Merck’s ADC Pact With Daiichi Hits Regulatory Setback in FDA Rejection  BioSpace

Japanese pharma firm Daiichi Sankyo sets up new research sites in US, Germany - BioSpectrum Asia

Japanese pharma firm Daiichi Sankyo sets up new research sites in US, Germany  BioSpectrum Asia

Daiichi Sankyo Drops $1B to Boost ADC Manufacturing Capacity at German Site - BioSpace

Daiichi Sankyo Drops $1B to Boost ADC Manufacturing Capacity at German Site  BioSpace

Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug Ezharmia - Fierce P...

Daiichi Sankyo bags an industry first with Japanese nod for blood cancer drug Ezharmia  Fierce Pharma

Daiichi Sankyo’s FLT3 Inhibitor Gets FDA Nod as First-Line AML Treatment - BioSpace

Daiichi Sankyo’s FLT3 Inhibitor Gets FDA Nod as First-Line AML Treatment  BioSpace

USPTO Rules Against Seagen in ADC Patent Battle with Daiichi Sankyo - BioSpace

USPTO Rules Against Seagen in ADC Patent Battle with Daiichi Sankyo  BioSpace